FINWIRES · TerminalLIVE
FINWIRES

Axon Enterprise's Q1 Outperformance Strengthens Case for Durable Growth, Morgan Stanley Says

By

-- Axon Enterprise's (AXON) Q1 performance, specifically in bookings, strengthens its case for durable growth of over 30%, Morgan Stanley said in a Thursday note.

The company once again posted a strong quarter, with revenue growth of 34% marking the ninth straight quarter of 30%-plus growth, Morgan Stanley analysts said. They noted that bookings greatly surpassed expectations with an increase of 44%, benefiting from developments in artificial intelligence.

Axon's growth expanded across several segments, as Dedrone bookings surged 500% year over year, international sales doubled, and enterprise rose 50%, the analysts noted.

The recent results support Morgan Stanley's view that Axon can keep delivering elevated growth as its platform diversifies beyond core US state and local law enforcement into new areas such as global markets, federal agencies, enterprises, drone technology, and 911 systems, according to the note.

Morgan Stanley maintained the company's stock rating at overweight and lowered the price target to $600 from $675.

Price: $434.70, Change: $+48.84, Percent Change: +12.66%

Related Articles

Australia

CVS Health Increasingly Likely to Reach 3% Medicare Advantage Target Margin in 2028, RBC Says

CVS Health (CVS) is increasingly more likely to reach its 3% Medicare Advantage target margin in 2028, RBC Capital Markets analyst said in a note Wednesday.Analysts said the company's Q1 adjusted earnings "comfortably" beat expectations, driven by "strong" topline growth and a notable improvement in profitability in the Health Care Benefits segment.Medical costs came in below expectations and, while the company maintained its medical benefit ratio guidance for the year, it is increasingly likely to outperform, according to the note.The brokerage raised its 2026 adjusted earnings estimate for the company to $7.41 from $7.10. Analysts surveyed by FactSet expect $7.29.RBC reiterated its outperform rating on the stock and increased its price target to $107 from $93.Price: $87.01, Change: $+0.14, Percent Change: +0.17%

$CVS
Research

Research Alert: CFRA Maintains Strong Buy Rating On Shares Of Trimble Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $86, from 85, on a forward P/E of 21x our 2027 EPS projection of $4.08, below historical averages. We increase our 2026 EPS projection to $3.59 from $3.52, and lift our 2027 EPS estimate to $4.08 from $4.06. TRMB reported solid Q1 beats with revenue of $939.9M, up 12% Y/Y, led by AECO at 14% organic revenue and ARR growth, Field Systems posting 12% growth, and Transportation & Logistics growing 7% despite freight market headwinds. ARR reached a record $2.435B, up 13% organically, reinforcing business model durability. Non-GAAP operating margin improved 230 bps to 25.9%, while non-GAAP gross margins expanded 180 bps to 71.0%, and we see continued margin expansion as its subscription revenues scale. We note steady execution in its core business, while building AI momentum through new products and partnerships with AI labs. Management reaffirmed its 2027 targets, supporting our positive view, though macro risks warrant monitoring.

$TRMB
Australia

Apollo Global Trades at Lower Discount Versus Peers, RBC Says

Apollo Global Management (APO) shares are trading in-line with historical average multiple and at a lower discount against its peers, RBC Capital Markets said in a Thursday note."We maintain our Sector Perform rating largely driven by relative valuation," the report said.The note said its Q1 performance was characterized by strong fee-related earnings growth, offset by weak spread-related earnings growth, driving a low adjusted net income per share growth.RBC raised its price target to $146 from $139 on rolling forward its valuation and higher estimates.Price: $127.33, Change: $-2.20, Percent Change: -1.70%

$APO